According to a recently published report, the Global Chronic Myeloid Leukemia (CML) Market is expected to grow at the CAGR of -3.4% during 2017-2025. The global chronic myeloid leukemia market is segmented on the basis of type of treatment, and geography. The report on global chronic myeloid leukemia (CML) market forecast 2017-2025 (by drugs, and geography) provides a detailed overview and predictive analysis of the market.
Full report available Global Chronic Myeloid Leukemia (CML) Market 2017 – 2025 (by drugs, and geography) report at http://www.briskinsights.com/report/chronic-myeloid-leukemia-cml-treatment-market
Market Insights
In chronic myeloid leukaemia (CML) the bone marrow carries out uncontrolled production of white blood cells or granulocytes so much that it gradually crowd the bone marrow, interfering with normal blood cell production. In most of the chronic cases these cells also spill out of the bone marrow and circulate around the body in the bloodstream. Due to improper growth of white blood cells, they are unable to function properly to fight infections leading to a shortage of red blood cells and platelets leading to anemia, bleeding and/or bruising. According to market experts, since last decade exceptional progress has been carried out in the field of chronic myeloid leukemia (CML) treatment by providing multiple treatment options to patients. In 2016, it was observed that BCR-ABL inhibitors accounted for the largest market share in CML treatment with first-generation imatinib and more effective second-generation BCR-ABL inhibitors such as nilotinib and dasatinib. However, the new members of BCR-ABL inhibitors class such as ponatinib and bosutinib have been recently approved for market inclusion. A few research studies suggested that nilotinib and dasatinib possesses high efficacy than imatinib in first-line chronic-phase CML (CML-CP) treatment, which is expected to give comparatively more rapid responses along with enhanced results in patients. The application of second- and third-generation therapies occurs in patients which are unable to gain sufficient benefits from Imatinib. The market stakeholders consider that the more potent second- and third-generation products have an opportunity to be used more widely due to a few properties possessed by these products to deliver a deeper and faster response, which could potentially prolong overall survival.
In year 2016, North America was observed as the largest CML treatment market due to key driving factors such as increasing early diagnosis rate in patients suffering from cancer, high public awareness in CML patients related to novel drug treatments and highest yearly treatment expense compared to others regions. The American Cancer Society estimates that in year 2016, about 8,220 new cases have been diagnosed with CML (4,610 in men and 3,610 in women), and about 1,070 people died of CML (570 men and 500 women). Thus, North America is expected to retain its domination in the near future.
Browse here for Same category Reports : http://www.briskinsights.com/category/pharmaceutical-industry
Scope of the report
1. Global Chronic Myeloid Leukemia (CML) Market, By Treatment Type, 2015–2025 ($ Millon)
1.1. Targeted Therapy
1.1.1. Imatinib
1.1.2. Dasatinib
1.1.3. Nilotinib
1.1.4. Bosutinib
1.1.5. Ponatinib
1.2. Chemotherapy
1.3. Radiation Therapy
1.4. Splenectomy
1.5. Stem Cell Transplant
2. Global Chronic Myeloid Leukemia (CML) Market, By Geography, 2014-2024 ($ Millon)
2.1. North America
2.2. Europe
2.3. Asia Pacific
2.4. Latin America (LATAM)
2.5. Middle East and Africa (MEA)
3. Company Profiles
3.1. Novartis AG
3.2. Bristol-Myers Squibb
3.3. Teva Pharmaceuticals Industries Ltd.
3.4. ARIAD Pharmaceuticals, Inc.
3.5. Pfizer, Inc.
3.6. Hospira, Inc.
3.7. Prism Pharmaceuticals
3.8. Incyte Corporation
3.9. Bio-Path Holdings
3.10. Stragen Pharma SA
3.11. Otsuka Pharmaceutical Co., Ltd.
Download Free Request Sample :http://www.briskinsights.com/sample-request/598
About Us :
Brisk Insights is a global market research firm. Our insightful analysis is focused on developed and emerging markets. We identify trends and forecast markets with a view to aid businesses identify market opportunities optimize strategies.
Working in a highly dynamic and multi-dimensional business makes decision making complex. Effective business decisions are a result of the synthesis of market information. Our Research and data analysis is an efficient and cost-effective way of providing robust market analysis and can yield highly valuable intelligence relating to consumers, competitors and markets.
Contact Us :
Jennifer Smith
Office 1094
109 Vernon House
Friar Lane
Nottingham
NG1 6DQ
United Kingdom
Phone : +448081890034 (UK)
Email : sales@briskinsights.com
Website : http://www.briskinsights.com/